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Abstract
Aims/hypothesis The aim of the study was to determine the
prevalence of depression in insulin-naive diabetes patients
and to investigate the associations between different forms
of vascular co-morbidity and depression.
Methods Cross-sectional data were used from a primary-
care sample of 1,269 insulin-naive (i.e. not using insulin
therapy) diabetes patients participating in the DIAZOB
Primary Care Diabetes study. Demographics, vascular co-
morbidities, clinical and lifestyle characteristics, and psycho-
social factors were assessed. Depression symptoms were
measured with the Edinburgh Depression Scale, with a score
>11 defined as depression. The χ
2 and Student’s t tests were
used to compare groups with and without vascular co-
morbidities. Rates and odds ratios of depression were
calculated for each vascular co-morbidity, with diabetes only
as the reference group, correcting for age and sex. Single and
multiple logistic regression analyses were performed to test a
more comprehensive model regarding the likelihood of
depression in diabetes.
Results The prevalence of depression was 11% in the total
sample with little difference between the groups with and
without any vascular co-morbidity (11.2% vs 10.0%). Single
vascular co-morbidities were not associated with increased
rates of depression. The final model predicting depression
included: having multiple vascular co-morbidities compared
with none; having less social support; having experienced a
recent stressful life event; female sex; and being a smoker.
Conclusions/interpretation Rates of depression in those
with one additional vascular co-morbidity did not differ
from patients with diabetes only. Vascular co-morbidities





DIAZOB Diabetes Care Zuidoost Brabant
EDS Edinburgh Depression Scale
LADA Latent autoimmune diabetes in adults
PAD Peripheral arterial disease
Introduction
Depression is one of the leading contributors to the burden of
disease worldwide, and it is an important cause of disability
[1]. There is mounting evidence that depression is more
common in people with type 2 diabetes [2]. Depression in
people with diabetes is associated with a decreased quality of
life [3], poor glycaemic control [4], increased healthcare
costs [5] adverse health outcomes and a higher mortality
risk [6, 7].
The reasons for the increased prevalence of depression in
type 2 diabetes are still not fully understood, but the general
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DOI 10.1007/s00125-009-1460-2notion is that the burden of having diabetes, and particu-
larly having complications of diabetes, plays an important
role in the aetiology of depression in diabetes. For example,
a Dutch study showed that the prevalence of depression
was particularly high in diabetes patients with co-morbid
medical disease(s) (20%), compared with patients with type
2 diabetes only (8%) or no chronic disease at all (9%) [8].
This was confirmed in a meta-analysis in which depression
was significantly associated with the presence of several
macro- and microvascular diabetes complications [9].
It is important to emphasise that the studies that were
included in the meta-analysis of Ali et al. [2], were based
on data from relatively small samples of patients with type
2 diabetes. This obviously prevented adequate detection of
potential confounding factors in the pooled population.
Little research has been performed in patients with type 2
diabetes in which the odds for depression are corrected for
potential confounders, particularly those involving the
coexistence of vascular diseases [8, 10–15]. The sole large
population-based primary-care sample included in the meta-
analysis above [2] did provide adjusted and unadjusted
rates of depression and corrected for cardiovascular disease,
but not for other diabetes related complications [16].
Additionally, Egede et al. (2005) are probably the only
authors who identified the contribution of specific chronic
conditions to depression [11]. However, the authors did not
discriminate between type 1 and type 2 diabetes, nor did
they examine the contribution of specific co-morbidities to
depression. Finally, none of the previous studies was
conducted in insulin-naive (i.e. not using insulin therapy)
diabetes patients only. Patients on insulin therapy may have
an increased likelihood of depression, as a result of their
longer diabetes duration and increased disease severity.
Moreover, insulin therapy is generally regarded as more
demanding in comparison with oral agents or diet only [17].
Therefore, the main aims of the present study were to
determine the prevalence of depression in a large well-
defined population of insulin-naive diabetes patients,
comparing patients with diabetes only with those with
vascular co-morbidity and to determine the associations




The data collection for this study was anchored in general
practice which is, in the Dutch healthcare system, the main
provider of care and the gatekeeper of access to specialist
medical care [18]. Accordingly, in the Netherlands 80–85%
of diabetes management is sited in general practice,
whereas complicated diabetes patients (type 1/type 2) are
generally treated in secondary care by an internist [19].
Data were collected between September and December
2005 from a cohort (n=1,770) of patients diagnosed with
diabetes in a large ongoing diabetes routine primary-care
programme ‘DIAZOB’ (Diabetes Care Zuidoost Brabant)
[20]. To assemble this cohort, all patients diagnosed with
diabetes registered with 77 general practitioners in the
Eindhoven region (n=2,470), the Netherlands, were invited
by their diabetes-management-trained nurse practitioner to
join this project during their regular diabetes check-up. The
intention is to follow this cohort during their lifetime, and
to assess biological, demographic, psychosocial, and
lifestyle variables periodically at 1 year intervals.
Diabetes was diagnosed and classified according to the
WHO guidelines (1999) [21]. These guidelines do not
include the measurement of C-peptides or anti-GAD or other
antibodies and therefore about 10% of the patients diagnosed
with type 2 diabetes may have latent autoimmune diabetes in
adults (LADA) [22]. The rates of vascular complications are
similar for LADA and type 2 diabetes [23].
For the purpose of this study, only insulin-naive patients
were included in the analyses, thereby excluding 117 (7%)
patients using insulin. As we were not able to discriminate
between type 2 diabetes and LADA we use the term
‘insulin-naive diabetes patients’ instead of ‘insulin-naive
type 2 diabetes patients’. After exclusion of responders who
gave no informed consent (n=90), and after excluding
patients with data missing from their records (n=294), the
study sample included 1,269 participants. The study
protocol was approved by the ethics committee of the
Máxima Medical Centre Veldhoven, the Netherlands,
located in the DIAZOB region. All 1,269 participants gave
written informed consent.
Assessments Demographic variables (age, sex, marital status
and educational level), and lifestyle factors (smoking status and
alcohol consumption) were assessed by a nurse-led interview.
Marital status was dichotomised as being single vs being
with a partner. Educational level was classified as low
education (i.e. primary school, pre-vocational education) vs
middle/high education. Smoking status was assessed as
current smoker (yes/no) and alcohol consumption was
assessed as number of drinks consumed per week.
Vascular co-morbidities Vascular co-morbidities, including
coronary heart disease, peripheral arterial disease (PAD),
stroke, neuropathic foot, ischaemic foot, retinopathy and
nephropathy, were assessed during an interview led by the
nurse practitioner, who also checked this information in the
medical files of the general practitioner.
Coronary heart disease and stroke were diagnosed in
hospital by angiography and ECG, and angiography and
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ing (MRI), respectively.
Peripheral arterial disease, atherosclerosis distal to the
aortic bifurcation, was diagnosed by a general practitioner or
vascular surgeon using the ankle–arm index. An ankle–arm
index of <0.90 indicates peripheral arterial disease, and this
can be divided into four stages (1, 2, 2a, 2b, 3 and 4) of
increasing severity. Stages 3 and 4 of peripheral arterial
disease (systolic ankle pressure <50 mmHg) include ischae-
mic foot and foot ulcer, which in this study were grouped as
‘ischaemic foot’ [24]. Ischaemic foot was diagnosed by a
podotherapist specialising in diabetes. Neuropathic foot was
diagnosed according to the national guideline for the diabetic
foot by a specialist podotherapist [25, 26].
Nephropathy was diagnosed according to the national
guideline for diabetic nephropathy [27, 28], using the
albumin–creatinine ratio and a calculation of the glomerular
filtration rate assessed by the Cockcroft–Gault formula [29].
Retinopathy was diagnosed by a specially trained
biometrist or an ophthalmologist by means of fundus
photography according to the national guideline for diabetic
retinopathy [30, 31].
All vascular co-morbidities were recorded using the same
definitions by all the healthcare professionals involved.
Finally, the variable ‘number of vascular co-morbidities’
was obtained by summing the vascular co-morbidities as
defined above.
Other clinical characteristics HbA1c and body mass index
(kg/m
2) values were collected at the Diagnostic Centre
Eindhoven, the Netherlands, a primary-care diagnostic
institute responsible for the periodic assessment of biological
variables as well as eye and foot examinations in patients
with diabetes. HbA1c was measured using the ion-exchange
high performance liquid chromatography method.
Both HbA1c and BMI were included in the analyses as
continuous variables.
Psychosocial factors Depressive symptoms during the last
week were assessed using the Dutch validated version of the
Edinburgh Depression Scale (EDS) (Cronbach’s alpha 0.84)
[32–36], which was originally designed to assess postpartum
depression, but which has been validated in other age strata
[37–39], and in men [36]. This is a ten-item self-rating scale
in which each item is scored on a four-point Likert scale.
Total scores range from 0 to 30 points, in which a score
higher than 11 points indicates the presence of depression.
This cut-off was also used in the present study. In general, up
to 50% of participants with scores higher than 11 on the
EDS suffer from syndromal major depression [37].
Social support was determined by three items adapted
from O’Hara et al. (Cronbach’s alpha 0.87), namely: ‘There
are many people that I can count on’, ‘There is always
someone that I can talk to about my day to day problems’,
and ‘There are plenty of people that I can lean on in case of
trouble’ [40]. Response categories range from zero to four
points, in which a score of zero points indicates ‘no social
support at all’ and a score of four points indicates
‘extensive social support’. Social support was measured
using the sum of the three items.
Furthermore, respondents were asked if they had
experienced a stressful life event (yes/no) in the previous
12 months (e.g. loss of a loved one, a divorce, loss of their
job, serious financial problems or physical/mental abuse).
The number of stressful life events was summed.
Statistical analyses
Differences in demographic, clinical and lifestyle character-
istics between the group with and without co-morbidity
were analysed using χ
2 or Fisher’s exact test when
appropriate for categorical data and the Student’s t test for
continuous data.
Logistic regression analyses adjusted for sex and age
(ORs with 95% confidence intervals) were performed for
each vascular co-morbidity separately with depression as
the dependent variable. The group with diabetes without
vascular co-morbidities was used as a reference group and
was compared with the group with a specific vascular co-
morbidity (e.g. stroke) with and without co-existing
vascular diseases. Finally, to assess the relative importance
of potential confounders and risk factors of depression,
single and multiple logistic regression (backwards) analyses
were performed in the total group by including the following
independent variables: age, female sex, being single, low
education, quantity of vascular co-morbidities, treatment
with oral hypoglycaemic medication, HbA1c,B M I ,s m o k i n g
status, alcohol intake, social support and having experienced
a recent stressful life event. In order to deal with possible
multiplicity issues, we applied a Bonferroni correction
testing at a significance level of α (0.05)/k (number of tests)
to lower the chance of a type 1 error.
Prior to these analyses, possible multi-colinearity was
examined using the variance inflation factor as a diagnostic
factor. However, this was found not to occur. Analyses




The study sample (n=1,269) was predominantly white
(98%), with an equal sex distribution. Mean age (±SD) was
66±10 years, and the mean HbA1c level was 6.7%. About
2058 Diabetologia (2009) 52:2056–206358% had had diabetes for more than 3 years. The
prevalence of depression in the total study sample was
11% (men 7%; women 14%; p<0.001).
Between-group differences
The characteristics of the study sample are summarised in
Table 1. In total, 562 patients (44%) had diabetes without
vascular co-morbidity. Of the remaining 707 patients, 431
(61%) had one vascular disease, while 276 (39%) had two
or more vascular co-morbidities. The prevalence of macro-
vascular disease ranged from 7% (stroke) to 22% (PAD and
CHD) of the total sample, whereas microvascular disease
was diagnosed in 3% (ischaemic foot) to 25% (neuropathic
foot) of the total sample. Patients with vascular disease
were significantly older, and were more frequently men and
single. As can be seen in Table 1, the prevalence of
depression did not differ significantly between the group of
patients without vascular co-morbidities and those with
vascular co-morbidities for the group as a whole (10.0% vs
Table 1 Characteristics of participants without (n=562) and with (n=707) vascular co-morbidity
Characteristic Diabetes patients
Without vascular co-morbidity n (%) With vascular co-morbidity n (%)
Demographic features
White 550 (97.9) 688 (97.3)
Female sex 305 (54.3) 329 (46.5)*
Age (mean, SD) 62.6 (10.1) 68.7 (9.4)
a
Low education 343 (61.0) 452 (63.9)
Single status 105 (18.7) 186 (26.3)
a
Clinical characteristics
Diabetes duration (>3 years) 320 (56.9) 418 (59.1)
Treatment with oral hypoglycaemic medication 444 (79.0) 582 (82.3)
HbA1c (mean, SD) 6.6 (0.8) 6.7 (0.8)
BMI (mean, SD) 29.1 (4.7) 28.8 (4.5)
Psychosocial factors
Depression score EDS (mean, SD) 5.6 (4.7) 5.8 (4.6)
EDS score >11 56 (10.0) 79 (11.2)
Social support (mean, SD) 7.8 (3.1) 8.1 (2.9)
Recent stressful life event (previous 12 months) 188 (33.5) 243 (34.4)
Lifestyle factors
Current smoker 93 (16.5) 97 (13.7)*
Alcohol intake (>14 consumptions/week) 40 (7.1) 54 (7.6)
Vascular co-morbidities
b
Macrovascular diseases 457 (36.0)
Peripheral arterial disease – 274 (21.6)
Coronary disease – 274 (21.6)
Stroke – 85 (6.7)
Microvascular diseases 422 (33.3)
Neuropathic foot – 312 (24.6)
Ischaemic foot – 34 (2.7)
Retinopathy – 73 (5.8)
Nephropathy – 48 (3.8)
Number of vascular co-morbidities
1 – 431 (34.0)
2 – 183 (14.4)
≥3 – 93 (7.3)
aSignificant after Bonferroni correction (p<0.0033) (α=0.05/15 tests=0.0033)
bVascular co-morbidities: rates are depicted as proportion of total population (n=1,269)
*p<0.05
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and women (13.1 vs 15.5%, p=0.39) separately (data not
shown).
Prevalence of depression per vascular disease
Table 2 shows the rates and the likelihood (adjusted for age
and sex) of depression for each vascular disease separately.
As 39% of the patients with vascular co-morbidities had
multiple vascular co-morbidities, the prevalence and the
likelihood of depression are shown for the group with one
specific vascular disease only, and the group with this same
vascular disease together with one or more co-existing
vascular co-morbidities. Except for the group with CHD
only (13.3%), and the group with retinopathy only (10.7%),
the prevalence of depression tended to be lower in the
groups with only one co-existing vascular disease com-
pared with the group having only diabetes. However, apart
from the two above-mentioned exceptions, the co-existence
of multiple vascular co-morbidities at least doubled the
prevalence of depression compared with having only one
specific vascular co-morbidity. CHD and neuropathic foot
in co-existence with other vascular co-morbidities were
significantly associated with depression (p<0.05); however,
this significance did not remain after the Bonferroni
correction (Table 2).
Multiple logistic regression analyses
The single associations between each independent variable
and depression as well as the results of the multiple logistic
regression analyses are shown in Table 3. The stepwise
backward elimination analyses (OR, 95% confidence
interval) show that in the final model (omnibus test of
model coefficients: χ
2 107.13, df 14, p<0.001) depression
was significantly predicted by having two (OR 2.50)
vascular co-morbidities, lower social support (OR 1.29),
having experienced a stressful life event in the previous
12 months year (OR 2.24), female sex (OR 2.98), and
current smoking (OR 2.31), after Bonferroni correction.
Discussion
In the present study, the prevalence of depression in insulin-
naive diabetes patients was 11%, which was lower than the
prevalence reported in a previous meta-analysis (17%) and
the rates reported in two previous studies in Dutch type 2
diabetes patients [2, 8, 14]. It was even comparable with the
prevalence of depression in non-diabetic individuals and
type 2 diabetes patients without co-morbidities [2, 8].
Furthermore, results of our study show that the prevalence
of depression was not increased in insulin-naive diabetes
Table 2 Rates and odds for participants with a specific vascular disease (with and without co-existing vascular diseases) compared with
participants without vascular co-morbidity
Co-existing vascular diseases n Depression (EDS score >11)
Prevalence (%) Adjusted OR (95% CI)
a
Diabetes only (reference group) – 562 10.0 1.0
Macrovascular diseases
Peripheral arterial disease No 81 6.2 0.61 (0.23–1.57)
Yes 193 11.9 1.58 (0.90–2.76)
Coronary disease No 90 13.3 1.72 (0.85–3.52)
Yes 184 14.7 2.03 (1.18–3.48)
b
Stroke No 28 7.1 0.87 (0.20–3.83)
Yes 57 14.0 2.07 (0.88–4.89)
Microvascular diseases
Neuropathic foot No 166 9.6 1.22 (0.65–2.30)
Yes 146 13.0 1.87 (1.06–3.51)
b
Ischaemic foot No 20 5.0 0.70 (0.09–5.47)
Yes 14 14.3 1.67 (0.35–8.08)
Retinopathy No 28 10.7 1.02 (0.30–3.53)
Yes 45 15.6 2.25 (0.90–5.64)
Nephropathy No 18 5.6 0.58 (0.08–4.57)
Yes 30 20.0 2.38 (0.89–6.35)
aAdjusted for sex and age
bSignificant odds ratio (p<0.05), but not after Bonferroni correction (p<0.0036) (α=0.05/14 tests=0.0036)
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Further, more detailed, analyses demonstrated that the
presence of multiple vascular co-morbidities approximately
doubled the likelihood of depression. However, the associ-
ation between having three or more comorbidities and
depression was not significant after Bonferroni correction
(p=0.047), which may due to a lack of statistical power as
this group is relatively small.
In line with the findings of previous research [8, 11, 13,
41], the number of vascular co-morbidities was related to
higher levels of depression. For example, in one of these
studies, the risk of developing depression was increased in
patients with three or more vascular co-morbidities [41].
However, in another study, the number of diabetes co-
morbidities was associated with major depression in men
only, and with minor depression in older patients only [13].
We believe that there are two main explanations for our
finding that depression was more common in patients with
multiple vascular co-morbidities. First, the burden of
having several chronic diseases may have contributed to
feelings of depression. Second, there may also be biological
mechanisms that have an important role in the pathophys-
iology of type 2 diabetes and cardiovascular disease, as
well as in depression. For example, an ongoing cytokine-
induced acute phase response appears to be closely
involved in the pathogenesis of type 2 diabetes and
associated complications [42]. Considerable evidence has
accumulated over the past decade that the atherosclerotic
process is regulated by inflammatory mechanisms. Cardio-
vascular disease is increasingly being viewed as a chronic
inflammatory response to injuries of the vascular endothe-
lium [43]. In the field of psychiatry, depressed patients have
been found to have higher levels of cytokines, acute phase
proteins, chemokines and cellular adhesion molecules [44].
It should be noticed that the current primary care sample
consisted of insulin-naive patients with relatively ‘uncompli-
cated’ diabetes. As could be expected, the proportion of
patients with vascular co-morbidities was still relatively low
(56%). In other studies the percentages of patients with co-
morbiddisease typically rangedfrom69% to75% [8, 11–13].
Except for the number of vascular co-morbidities, no
other diabetes-specific factors were associated with depres-
sion. This is in contrast with the conclusion of a meta-
analysis that elevated HbA1c levels were associated with
higher levels of depression [45]. We believe our result may
reflect the relatively good glycaemic control in our sample.
Similarly, BMI was not associated with depression, which
was similar to the result in another study [46] in diabetes
patients, but in contrast with the results from two other
studies in this patient group [13, 16]. In general, studies of
Table 3 Single and multiple logistic regression predicting depression by demographic features, vascular co-morbidity, clinical and lifestyle
characteristics, and psychosocial factors in insulin-naive diabetes patients (n=1,269)
Variable Single logistic regression models
(OR, 95% CI)
Multiple logistic regression models
(method backwards) (OR, 95% CI)
Demographic features
Age 0.99 (0.98–1.01)
Female sex 2.25 (1.54–3.29)
a 3.29 (2.08–5.18)
a
Being single 1.48 (0.99–2.20)
Low education 1.72 (1.13–2.62)*
Vascular co-morbidities
0 1.00 1.00
1 0.92 (0.60–1.42) 1.07 (0.64–1.77)
2 1.63 (1.00–2.66)* 2.50 (1.40–4.46)
a
≥3 1.21 (0.61–2.41) 2.23 (1.01–4.93)*
Clinical and lifestyle factors
Treatment with oral hypoglycaemic medication 1.11 (0.70–1.76)
Higher HbA1c 1.03 (0.83–1.28)
Higher BMI 0.99 (0.95–1.03)
Current smoker 1.57 (1.00–2.46)* 2.31 (1.37–3.91)
a
Alcohol intake >14 consumptions/week 0.55 (0.24–1.29)
Psychosocial factors
Lower social support 1.26 (1.19–1.35)
a 1.29 (1.20–1.38)
a
Recent stressful life event 2.55 (1.78–3.66)
a 2.24 (1.47–3.40)
a
aSignificant odds ratio after Bonferroni correction (p<0.0033; α=0.05/15 tests=0.0033)
*Significant odds ratio (p<0.05)
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have shown mixed results. Some have found a positive
association, while others have found a negative association
between overweight and depression (supporting the ‘jolly
fat’ hypothesis), and some did not find an association at all
[47, 48]. In a meta-analysis of this subject, it was therefore
concluded that some may suffer psychological distress from
being overweight/obese while others may not. More exten-
sive studies are needed to identify factors that protect from or
increase vulnerability to psychological distress [47].
Finally, in the current study the low levels of social
support and the occurrence of major life events were also
strongly associated with depression, which has also been
reported in the literature of depression in general.
A major strength of our study is the detailed documen-
tation of the presence specific vascular co-morbidities.
Other strengths are the relatively large sample size and the
homogeneous character of the sample of insulin-naive
diabetes patients.
However, some limitations need to be mentioned. First,
the cross-sectional design does not allow for making causal
inferences, such as statements on whether co-morbidities
preceded depression or vice versa. Second, although the
total sample was relatively large, it was difficult to identify
the contribution to depression of the individual vascular co-
morbidities, as they are often accompanied by other
vascular co-morbidities. The lack of significant associations
between the individual vascular co-morbidities and depres-
sion may therefore be partly explained by the low number
of cases with the separate specific vascular co-morbidities
within the total sample. Third, depressive symptoms rather
than syndromal depression were assessed. For obvious
reasons, in large samples, self-rating scales are preferen-
tially used. Fourth, we did not measure anti-GAD antibody,
and some of the patients in our sample may have LADA
rather than type 2 diabetes. In the UK Prospective Diabetes
Study, for example, about 10% of participants with
presumed type 2 diabetes had evidence of islet autoimmu-
nity [22]. In the Hoorn study, a large population-based
study of diabetes patients aged 50–74 years in Dutch
primary care, anti-GAD antibodies were also measured
[49]. The patients with known diabetes in the Hoorn study
sample are comparable with the participants with diabetes
in our DIAZOB study. In the Hoorn study, the prevalence
of GAD65-A was 1% in participants with normal glucose
tolerance, 2% in those with impaired glucose tolerance, 0%
in patients with screen-detected diabetes, and 4% in patients
with known diabetes. Moreover, both studies showed that
GAD65-A was strongly associated with insulin use in
known diabetic individuals [22, 49], with 84–94% of the
patients with LADA progressing to insulin therapy within
6 years [22]. Based on these findings we can assume that
the proportion of patients with LADA in our study sample
of non-insulin-using diabetes patients will be rather low,
with about 90–95% of the patients having type 2 diabetes.
Finally, the duration of each vascular co-morbidity was
not recorded, which may confound the relationship between
the presence of vascular co-morbidities and depressive
symptoms.
In conclusion, in the current relatively healthy primary-
care sample, rates of depression in insulin-naive diabetes
patients with vascular co-morbidities were not higher than
in patients without vascular co-morbidities. However, more
detailed analyses showed that having multiple vascular co-
morbidities, and in particular coronary heart disease or
neuropathic foot combined with other vascular diseases,
increased the likelihood of depression compared with
having diabetes without vascular co-morbidities.
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